高胆固醇血症男女性中他汀使用时长与类型及2型糖尿病长期风险:三项前瞻性队列研究结果
基于护士健康研究(NHS,30510人)、护士健康研究II(NHSII,21547人)和卫生专业人员随访研究(HPFS,9934人)中基线无糖尿病、心血管疾病和癌症的高胆固醇血症参与者,分析他汀使用与2型糖尿病长期风险。随访至2023年1月31日,共记录6762例新发2型糖尿病;校正BMI等混杂因素后,他汀使用者2型糖尿病风险显著高于非使用者(合并HR 1.40;95%CI 1.33,1.48),且使用时长越长风险越高。
要点
- 他汀使用者较非使用者2型糖尿病风险升高(合并HR 1.40;95%CI 1.33,1.48)。
- 使用时长1-5、6-10、11-15、>15年HR分别为1.36、1.41、1.60、1.76,呈线性趋势(P<0.001)。
- 10年使用高强度他汀HR 1.72(95%CI 1.46,2.04),低强度他汀HR 1.34(95%CI 1.15,1.56)。
核心结论
- 他汀使用与2型糖尿病的正相关随使用时长延长而更明显,且在不同类型他汀间存在差异。
- 作者认为,采纳并保持健康生活方式可作为他汀治疗期间预防糖尿病的可行方法。
研究设计与样本
- 分析护士健康研究(NHS;30510名参与者)、护士健康研究II(NHSII;21547名参与者)和卫生专业人员随访研究(HPFS;9934名参与者)中基线无糖尿病、心血管疾病和癌症的高胆固醇血症参与者。
- NHS和HPFS自2000年起、NHSII自1999年起每2年评估他汀使用情况。
- 新发2型糖尿病病例通过经验证的补充问卷确认,随访至2023年1月31日。
主要发现
- 随访最长23年,共记录6762例新发2型糖尿病病例。
- 校正BMI及其他潜在混杂变量后,他汀使用者较非使用者2型糖尿病风险显著升高(合并HR 1.40;95%CI 1.33,1.48)。
- 与非使用相比,他汀使用1-5、6-10、11-15和>15年的HR分别为1.36(95%CI 1.27,1.44)、1.41(95%CI 1.31,1.52)、1.60(95%CI 1.44,1.78)和1.76(95%CI 1.50,2.06),线性趋势检验均P<0.001。
- 与非使用者相比,10年使用特定类型他汀的2型糖尿病HR:瑞舒伐他汀1.99(95%CI 1.45,2.73)、洛伐他汀1.66(95%CI 1.12,2.47)、阿托伐他汀1.62(95%CI 1.39,1.89)、普伐他汀1.44(95%CI 1.06,1.97)、辛伐他汀1.37(95%CI 1.13,1.66)。
- 10年低强度他汀使用与2型糖尿病风险升高34%相关(HR 1.34;95%CI 1.15,1.56),10年高强度他汀使用与风险升高72%相关(HR 1.72;95%CI 1.46,2.04)。
关键数值与推荐
- 他汀使用者与非使用者10年2型糖尿病累积风险差异在生活方式最不健康的参与者中最明显(4.5% vs 3.1%)。
- 在坚持最健康生活方式的参与者中风险差异最小(1.0% vs 0.4%)。
临床怎么用
- 作者认为,采纳并保持健康生活方式可作为他汀治疗期间预防糖尿病的可行方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Findings from RCTs and observational studies indicate a positive association between statin use and risk of type 2 diabetes. Mendelian randomisation studies provide evidence to support that the effect is causal. However, little is known about the long-term effects, and data on different types of statins remain limited. METHODS: We analysed participants with hypercholesterolaemia from the Nurses' Health Study (NHS; 30,510 participants), the Nurses' Health Study II (NHSII; 21,547 participants) and the Health Professionals Follow-Up Study (HPFS; 9934 participants) who were free of diabetes, CVD and cancer at baseline. Statin use was assessed every 2 years starting in 2000 in the NHS and the HPFS and in 1999 in the NHSII. Incident cases of type 2 diabetes were confirmed by a validated supplementary questionnaire until the end of follow-up (31 January 2023). RESULTS: We documented 6762 incident type 2 diabetes cases during up to 23 years of follow-up. Compared with non-users, statin users had a significantly higher risk of type 2 diabetes after adjustment for BMI and other potential confounding variables (pooled HR 1.40; 95% CI 1.33, 1.48). Compared with non-use, durations of statin use of 1-5, 6-10, 11-15 and >15 years were associated with HRs of 1.36 (95% CI 1.27, 1.44), 1.41 (95% CI 1.31, 1.52), 1.60 (95% CI 1.44, 1.78) and 1.76 (95% CI 1.50, 2.06), respectively; significant linear trends were observed when the comparison included non-users and within statin users only (both ptrend<0.001). Compared with non-users, the HRs for type 2 diabetes associated with 10 year use of specific types of statins were 1.99 (95% CI 1.45, 2.73) for rosuvastatin, 1.66 (95% CI 1.12, 2.47) for lovastatin, 1.62 (95% CI 1.39, 1.89) for atorvastatin, 1.44 (95% CI 1.06, 1.97) for pravastatin and 1.37 (95% CI 1.13, 1.66) for simvastatin. Use of a low-potency statin for 10 years was associated with a 34% higher risk of type 2 diabetes (HR 1.34; 95% CI 1.15, 1.56), while use of a high-potency statin for 10 years was associated with a 72% higher risk (HR 1.72; 95% CI 1.46, 2.04). The difference in the 10 year cumulative risk of type 2 diabetes comparing statin users vs non-users was most pronounced in participants with the least healthy lifestyles (4.5% vs 3.1%), while the smallest risk differential was observed among participants who adhered to the healthiest lifestyles (1.0% vs 0.4%). CONCLUSIONS/INTERPRETATION: The positive association between statin use and type 2 diabetes was more pronounced with a longer duration of use, and the association varied across different types of statins. Adopting and maintaining a healthy lifestyle can serve as a viable approach to diabetes prevention during statin treatment.
引用
- Zhang Y, Li Y, Liu Y, et al. Duration and type of statin use and long-term risk of type 2 diabetes among men and women with hypercholesterolaemia: findings from three prospective cohorts. Diabetologia. 2025. PMID: 40316730. doi:10.1007/s00125-025-06441-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。